Evidence map›Paper›PMID 40937038›Full record

ArticleCirculation reports2025

Differences in P2Y

Shigeru Fujimoto, Yasuyuki Iguchi, Hiroshi Yamagami, Masatoshi Koga, Ryo Itabashi, Yusuke Yakushiji, Kazuma Kowata, Naoto Kimura, Yuka Terasawa, Takahiro Shimizu and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. P2YJournal of atherosclerosis and thrombosis · 2026
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shigeru FujimotoDepartment of Medicine, Division of Neurology, Jichi Medical University Tochigi Japan.
Yasuyuki IguchiDepartment of Neurology, The Jikei University School of Medicine Tokyo Japan.
Hiroshi YamagamiDepartment of Stroke Neurology, NHO Osaka National Hospital Osaka Japan.
Masatoshi KogaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan.
Ryo ItabashiStroke Center, Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University Iwate Japan.
Yusuke YakushijiDepartment of Neurology, Kansai Medical University Osaka Japan.
Kazuma KowataInstitute of Brain and Blood Vessels, Mihara Memorial Hospital Gunma Japan.
Naoto KimuraIwate Prefectural Central Hospital Iwate Japan.
Yuka TerasawaDepartment of Neurology, Brain Attack Center Ota Memorial Hospital Hiroshima Japan.
Takahiro ShimizuDepartment of Neurology, St. Marianna University School of Medicine Kanagawa Japan.
Yuichi MiyazakiShonan Kamakura General Hospital Kanagawa Japan.
Koichi OkiTokyo Saiseikai Central Hospital Tokyo Japan.
Osamu MasuoYokohama Municipal Citizen's Hospital Kanagawa Japan.
Hideki MatsuokaNational Hospital Organization Kagoshima Medical Center Kagoshima Japan.
Shuji ArakawaSteel Memorial Yawata Hospital Fukuoka Japan.
Toshihiro UedaSt. Marianna University Toyoko Hospital Kanagawa Japan.
Ryota TanakaDepartment of Medicine, Division of Neurology, Jichi Medical University Tochigi Japan.
Wataru HashimotoData Intelligence Department, Daiichi Sankyo Co., Ltd Tokyo Japan.
Satoru AbePrimary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd Tokyo Japan.
Go KatoPrimary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd Tokyo Japan.
Taketoshi FurugoriPrimary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd Tokyo Japan.
Kazumi KimuraDepartment of Neurology, Graduate School of Medicine, Nippon Medical School Tokyo Japan.
ACUTE-PRAS Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We previously reported that prasugrel treatment resulted in stable inhibition of platelet aggregation compared with clopidogrel in patients with acute large artery atherosclerosis (LAA) or high-risk transient ischemic attack (TIA). However, the differences by disease subtypes were not assessed. This subgroup analysis of the open-label ACUTE-PRAS study examined differences in P2Y Methods and Results: We measured platelet reaction units (PRU) by disease subtypes for each treatment arm. Eighty-eight patients were included in each treatment arm in the full analysis. In the prasugrel group, there were 61 (69.3%) patients with LAA and 27 (30.7%) patients with high-risk TIA. In the clopidogrel group, there were 64 (72.7%) patients with LAA and 24 (27.3%) patients with high-risk TIA. Among patients with LAA, PRU at Day 5 were numerically lower in the prasugrel group than in the clopidogrel group (arithmetic mean±standard deviation at Day 5: 128.8±49.0 vs. 178.9±60.5). In contrast, PRU at Day 5 were similar between prasugrel and clopidogrel in patients with high-risk TIA. Conclusions: Prasugrel may have the potential to elicit stronger platelet aggregation inhibitory effects compared with clopidogrel in patients with acute LAA.

Indexed as

ClopidogrelCYP2C19Large artery atherosclerosisPrasugrelTransient ischemic attack

Identifiers

PMID40937038
PMCPMC12421135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.